hank_denver — that is really helpful context on Semaglutide. Follow-up question: what labs did your doctor order to monitor this?
I am in a similar situation (just started) and trying to set realistic expectations.
To answer VanRx_Mike's question specifically:
From a clinical standpoint, Semaglutide cardiovascular is an area where we have good evidence.
The short answer: baseline labs + quarterly monitoring is the standard of care.
The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.
Relevant to Semaglutide cardiovascular — here is my latest bloodwork comparison:
Key improvements: A1C 7.6% → 5.5%, triglycerides 201 → 101 mg/dL, hsCRP 8.0 → 1.3 mg/L. All on tirzepatide for 17 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.
Slightly tangential to Semaglutide but pete_nash reminded me — what is the latest on the oral formulations?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.